ALNY Q2 2022 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$225M+1.9% YoY

Gross Profit

$184M81.8% margin

Operating Income

-$192M-85.3% margin

Net Income

-$277M-123.4% margin

EPS (Diluted)

$-2.29

QoQ Revenue Growth

+5.4%

Cash Flow

Operating Cash Flow

-$123M

Free Cash Flow

-$139M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$3.3B

Total Liabilities

$3.2B

Stockholders' Equity

$176M

Cash & Equivalents

$576M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$225M	$221M	+1.9%
Gross Profit	$184M	$182M	+1.2%
Operating Income	-$192M	-$146M	-31.1%
Net Income	-$277M	-$190M	-46.3%

Revenue Segments

Product

$214M99%

Royalty

$2M1%

Geographic Segments

Europe

$8M51%

UNITED STATES

$7M48%

Non-US Or Europe

$223,0001%